Finasteride is a selective inhibitor of the type II isoform of 5-alpha reductase, the enzyme responsible for converting testosterone to dihydrotestosterone (DHT) in androgen-sensitive tissues including the scalp. DHT binds androgen receptors in dermal papilla cells with higher affinity than testosterone and drives the progressive miniaturisation of genetically susceptible follicles that characterises AGA. By reducing DHT production at the enzyme level, finasteride removes the primary hormonal signal driving that miniaturisation.

Oral finasteride at 1mg daily reduces serum DHT by approximately 65 to 70% and scalp tissue DHT by a broadly similar proportion. The full molecular detail of the androgen pathway in AGA is covered in the article on DHT and the follicle.

The therapeutic target in AGA is the dermal papilla cell at the base of the scalp follicle. Oral finasteride reaches that target, but it also reduces DHT production throughout the body wherever type II 5-alpha reductase is expressed. Systemic DHT reduction is the source of both the drug's known side effects and the rarer reports of persistent symptoms.

The rationale for topical delivery is that direct application to the scalp allows finasteride to concentrate at the follicle while the amount absorbed systemically and reaching circulation is a fraction of an oral dose. If scalp DHT can be reduced to a clinically effective degree without proportionally suppressing serum DHT, the therapeutic benefit could in principle be maintained while substantially reducing the hormonal perturbation that generates side effects.

This is the pharmacological hypothesis that has driven two and a half decades of topical finasteride research, and the body of data that has accumulated broadly supports it, with caveats around study size, duration, and the challenge of making definitive claims about a smaller and rarer side effect profile in trials powered for efficacy endpoints.

Topical finasteride has been investigated across a range of concentrations and vehicle formulations. The trajectory from early proof-of-concept work at very low concentrations through to more recent randomised controlled trials reflects both growing confidence in the approach and evolution in understanding which vehicles best deliver the active to the follicle.

The Mazzarella et al. 1997 study is notable in particular because it demonstrated that a concentration of just 0.005%, two hundredths of the active ingredient found in the standard oral 1mg tablet, could produce hair growth outcomes that compared favourably with the oral form in the same trial. This was an early and important signal that the follicle could be engaged effectively with a much smaller absolute quantity of finasteride than oral dosing delivers systemically, provided the vehicle brought the active into close contact with scalp tissue.

Subsequent research has generally confirmed this principle while working to optimise the vehicle. Nanoemulsion formulations, which create microscopically small droplets of active-carrying oil suspended in an aqueous base, improved scalp penetration and drug delivery compared to earlier simple solution formulations. The 0.25% concentration now common in licensed and compounded topical finasteride products sits higher than the Mazzarella era concentrations, partly to ensure robust delivery even accounting for the losses inherent in surface application.

The most important pharmacological distinction between topical and oral finasteride is not the total amount of active delivered, but the ratio between local scalp effect and systemic effect. Studies measuring both scalp tissue DHT and serum DHT after topical application have consistently found that topical formulations can reduce scalp DHT to a substantial degree while producing markedly lower serum DHT suppression than oral finasteride at 1mg.

Oral finasteride 1mg reduces serum DHT by approximately 65 to 70%. Studies of topical finasteride have reported serum DHT reductions in the range of 7 to 30% depending on the formulation, concentration, and vehicle used, with some modern nanoemulsion studies at the lower end of that range. The plasma finasteride concentrations after topical application are similarly a fraction of those seen after oral dosing.

The practical implication is that topical finasteride sits on a spectrum between oral finasteride and no finasteride, rather than being a binary alternative. For someone whose primary concern is the systemic hormonal perturbation of oral dosing, topical substantially reduces but does not eliminate that perturbation.

The available evidence suggests topical finasteride produces meaningful hair growth outcomes in AGA, with hair count and hair width improvements demonstrated in trials including the Phase 3 RCT data. Direct head-to-head comparisons with oral finasteride are fewer and generally smaller than the oral finasteride evidence base, which spans three decades of large registrational trials.

The Mazzarella et al. comparison is instructive: at 0.005% topical versus oral 1mg, hair growth outcomes appeared broadly comparable within the limitations of that trial's population and design. More recent comparison data from studies of 0.25% formulations has largely supported this direction, with researchers reporting that the efficacy of topical appears to approach that of oral despite the substantially lower systemic exposure. However, the existing comparison trials are individually smaller and shorter than the landmark oral finasteride registrational studies, and the evidence base for topical efficacy, while growing, is not yet at parity with the oral data.

Response patterns appear broadly similar to oral finasteride: vertex thinning tends to respond better than temporal or frontal recession, earlier-stage loss is more responsive than advanced miniaturisation, and improvements in hair count and density accumulate over a minimum of six to twelve months of consistent use.

Clinical trials of oral finasteride at 1mg report sexual side effects (reduced libido, erectile dysfunction, ejaculatory disorders) in approximately 2 to 4% of users, though observational and community data suggest this figure may underrepresent real-world incidence. Post-finasteride syndrome, characterised by persistent sexual, neurological, and psychological symptoms following discontinuation, is a recognised condition that has generated its own research literature, though its precise incidence and causal mechanisms remain subjects of ongoing investigation.

Topical finasteride trials have generally reported lower rates of sexual side effects than the oral finasteride literature. This is consistent with the reduced systemic DHT suppression, and the mechanistic case for a better side effect profile is plausible. The important caveat is that topical studies are smaller and shorter than the three-decade oral database, which means they are not statistically powered to detect effects that occur in 1 to 3% of users with confidence. The apparent better tolerability of topical may reflect genuine pharmacological advantage, smaller sample size, or both.

Cases of sexual side effects with topical finasteride have been reported, consistent with the fact that some systemic absorption does occur. Topical is not side-effect-free; it is likely lower-risk for systemic effects, but that claim rests on a smaller evidence base than would be required to quantify the difference precisely.

Topical finasteride is not available as a widely stocked over-the-counter product in the UK. It is obtainable through compounding pharmacies (which prepare it to prescription specifications) and through some online hair loss clinics that prescribe and dispense it directly. It remains prescription-only regardless of route; the prescription requirement does not change simply because the formulation is topical.

Concentrations available through compounding are typically 0.1% or 0.25%, most commonly in a solution or spray vehicle. The cost is generally higher than generic oral finasteride, which is inexpensive, though the gap narrows when comparing to branded oral finasteride. Application is once daily to the affected scalp area; specific guidance varies by formulation and prescriber.

The same contraindications apply regardless of route: topical finasteride should not be handled by women who are pregnant or may become pregnant, due to the risk of feminisation of a male foetus. This is not specific to the oral route; it reflects the drug's mechanism and applies to any exposure. Some compounded products are supplied in pump dispensers specifically to avoid incidental skin contact by others in the household.

Topical finasteride is most clearly suited to three groups: people who have experienced sexual side effects on oral finasteride and wish to continue DHT suppression at lower systemic exposure; people who are interested in finasteride's efficacy but are concerned enough about side effects to prefer a reduced-systemic formulation from the outset; and people for whom oral finasteride is contraindicated or otherwise not suitable but who still require 5-AR inhibition as part of their protocol. For anyone weighing finasteride against dutasteride specifically, finasteride vs dutasteride: a direct comparison covers how the two compare on efficacy, side effects, and half-life.

It fits into the same position in a treatment protocol as oral finasteride: as the DHT-suppression component alongside minoxidil, topical actives such as the 1% AHK-Cu Hair and Scalp Serum, or microneedling, which address different dimensions of the scalp environment. The article on how to build a hair loss protocol covers how these layers interact. The broader AGA treatment landscape, including where DHT suppression fits relative to other options, is covered in the article on androgenetic alopecia: what it is, what causes it, and what the options are.

This article is provided for educational purposes and does not constitute medical advice. Finasteride is a prescription-only medication in the UK regardless of formulation; consult a qualified healthcare professional before use. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.